1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Somatropin For Injection (Single Dose Syringe: 0.2mg - 0.4mg)

Trade Name: Genotropin Miniquick®
Synonyms: Human Growth Hormone; HGH; Somatotropin
Chemical Family: Mixture
Intended Use: Pharmaceutical product for the treatment of human growth hormone deficiency.

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous</th>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somatropin</td>
<td></td>
<td>12629-01-5</td>
<td>235-735-8</td>
<td>12 - 22</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mannitol</td>
<td>69-65-8</td>
<td>200-711-8</td>
<td>*</td>
</tr>
<tr>
<td>Glycine</td>
<td>56-40-6</td>
<td>200-272-2</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, dibasic</td>
<td>7558-79-4</td>
<td>231-448-7</td>
<td>*</td>
</tr>
<tr>
<td>Water</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, monobasic</td>
<td>7558-60-7</td>
<td>231-449-2</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:
* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: White sterile lyophilized powder plus sterile diluent.
Signal Word: DANGER

Statement of Hazard:
Toxic if swallowed.
May cause allergic skin reaction.
Suspected of damaging fertility or the unborn child.

Additional Hazard Information:
Long Term: Animal studies indicate that this material may cause adverse effects on the blood, kidneys, liver, mammary gland.

Known Clinical Effects:
Adverse effects associated with the therapeutic use include glucose intolerance, fluid retention, headache and effects on the thyroid. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Drugs of this class may cause formation of antibodies.
MATERIAL SAFETY DATA SHEET

Material Name: Somatropin For Injection (Single Dose Syringe: 0.2mg - 0.4mg)
Revision date: 16-Feb-2007
Version: 2.1

EU Indication of danger: Irritant
Toxic to Reproduction; Category 3

EU Hazard Symbols: X

EU Risk Phrases: R43 - May cause sensitization by skin contact.
R62 - Possible risk of impaired fertility.
R63 - Possible risk of harm to the unborn child.


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.
Skin Contact: Remove clothing and wash affected skin with soap and water. If irritation occurs or persists, get medical attention.
Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.
Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products: No data available.
Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
Fire / Explosion Hazards: Not available

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Somatropin

Pfizer OEL TWA-8 Hr: 10ug/m³, Sensitizer

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Lyophilized powder plus sterile diluent

Color: White

Molecular Formula: Mixture

Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: No data available

Incompatible Materials: None identified

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Material Name: Somatropin For Injection (Single Dose Syringe: 0.2mg - 0.4mg) Revision date: 16-Feb-2007 Version: 2.1

Acute Toxicity: (Species, Route, End Point, Dose)

Mannitol
Rat  Oral  LD 50  13500 mg/kg
Mouse Oral LD 50 22 g/kg

Glycine
Rat  Oral  LD 50  7930 mg/kg
Mouse  Oral  LD 50  4920 mg/kg

Somatropin
Rat  Oral  LD50  242 mg/kg
Rat  Dermal  LD50  1100 mg/kg
Rat  Inhalation  LC50 1h  710 mg/m³
Mouse  Oral  LD50  828 mg/kg
Mouse  Intraperitoneal  LD50  828 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium phosphate, dibasic
Eye Irritation  Rabbit  Mild
Skin Irritation  Rabbit  Mild

Somatropin
Skin Irritation  Rabbit  Negative
Not specified  Guinea Pig  Positive
Antigenicity  Active anaphylaxis  Guinea Pig  Positive
Antigenicity  Passive cutaneous anaphylaxis  Guinea Pig  Positive

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Somatropin
1 Month(s)  Rat  Intramuscular  0.63 mg/kg/day  NOAEL  Mammary gland
3 Month(s)  Rat  Subcutaneous  0.37 mg/kg/day  LOAEL  Liver, Adrenal gland, Kidney
3 Month(s)  Monkey  Subcutaneous  0.125 mg/kg/day  LOAEL  Mammary gland, Blood
52 Week(s)  Monkey  Subcutaneous  0.63 mg/kg/day  NOAEL  Adipose tissue, Mammary gland, Reproductive system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Somatropin
Embryo / Fetal Development  Rat  Subcutaneous  3.3 mg/kg/day  NOAEL  Not teratogenic
Embryo / Fetal Development  Rabbit  Intramuscular  0.3 mg/kg/day  NOAEL  Not Teratogenic
Embryo / Fetal Development  Rat  Subcutaneous  3.3 mg/kg/day  LOAEL  Fetotoxicity
Reproductive & Fertility  Rat  Subcutaneous  0.3 mg/kg/day  NOAEL  Fertility
Peri-/Postnatal Development  Rat  Subcutaneous  3.3 mg/kg/day  NOAEL  No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Somatropin
Bacterial Mutagenicity (Ames)  Salmonella, E. coli  Negative
In Vitro Mammalian Cell Mutagenicity  Mouse Lymphoma  Negative
In Vivo Chromosome Aberration  Rat Bone Marrow  Negative
In Vitro Chromosome Aberration  Human Lymphocytes  Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xn
EU Indication of danger: Irritant
Toxic to Reproduction; Category 3

EU Risk Phrases:
R43 - May cause sensitization by skin contact.
R62 - Possible risk of impaired fertility.
R63 - Possible risk of harm to the unborn child.

EU Safety Phrases:
S36/37 - Wear suitable protective clothing and gloves.
S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:
DANGER
Toxic if swallowed.
May cause allergic skin reaction.
Suspected of damaging fertility or the unborn child.

Canada - WHMIS: Classifications

WHMIS hazard class:
D1b toxic materials
D2a very toxic materials
D2b toxic materials
16. OTHER INFORMATION

Reasons for Revision: Updated Section 3 - Hazard Identification. Updated Section 7 - Handling and Storage. Added Pfizer OEL (Section 8). Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 14 - Transport Information. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet